Diffuse alveolar hemorrhage associated with low molecular weight heparin

Area of Science:

• Pulmonary Medicine
• Hematology
• Pharmacology

Background:

• Diffuse alveolar hemorrhage (DAH) is a serious pulmonary complication with diverse causes.
• Anticoagulant medications, including heparin, are known potential triggers for DAH.
• Evidence comparing bleeding risks between low molecular weight heparin (LMWH) and unfractionated heparin remains inconclusive.

Purpose of the Study:

• To report a case of DAH potentially induced by enoxaparin, a type of LMWH.
• To highlight the association between LMWH use and DAH in the context of anticoagulation therapy.
• To raise awareness of DAH as a differential diagnosis in patients on LMWH presenting with acute respiratory failure.

Main Methods:

• Case report of a 74-year-old female patient.
• Administration of enoxaparin (LMWH) following bilateral total knee arthroplasty.
• Clinical observation and assessment of respiratory status, including development of ground-glass opacities.

Main Results:

• The patient developed DAH with bilateral lung ground-glass shadows and acute respiratory failure.
• While other factors like congestive heart failure were considered, LMWH cessation resulted in rapid clinical improvement.
• This suggests LMWH was a significant contributor to the DAH.

Conclusions:

• DAH should be considered in patients receiving LMWH who develop acute respiratory failure and bilateral lung infiltrates.
• LMWH, specifically enoxaparin, may be a direct cause of DAH.
• Prompt cessation of LMWH may lead to recovery from DAH.